Kidney Cancer Diagnostics Market Forecast to Reach USD 6.9 Billion by 2034, Growing at a Robust 6.2% CAGR Driven by Advanced Detection Technologies - TMR
The kidney cancer diagnostics market is poised for significant expansion, driven by an increase in the incidence of kidney cancer and a surge in diagnostic procedures. The global market, valued at US$ 3.6 Billion in 2023, is projected to grow at a 6.2% CAGR during 2024-2034, reaching US$ 6.9 Billion by the end of 2034. The timely diagnosis of kidney cancer enables prompt treatment decisions – including ablation, surgery, radiation therapy, immunotherapy, targeted drug therapy, and chemotherapy – ultimately improving patient survival rates.
The kidney cancer diagnostics market is experiencing robust growth driven by a significant increase in the number of kidney cancer cases worldwide. As more individuals are diagnosed each year, there is a pressing need for early and precise detection methods to improve patient outcomes. Advancements in diagnostic technology—ranging from biomarker-based assays and liquid biopsies to state-of-the-art imaging techniques like PET/CT scans—are enabling clinicians to identify malignancies earlier and with greater accuracy.
Explore core findings and critical insights from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=78590
These innovations not only facilitate personalized treatment strategies but also support the trend toward minimally invasive procedures, which are rapidly gaining favor among patients and healthcare providers alike. Alongside these technological improvements, widespread public health initiatives and educational campaigns have raised awareness about kidney cancer risk factors and early symptoms, leading to an increase in routine screenings. Collectively, these factors are significantly propelling the growth of the kidney cancer diagnostics market.
Analysts’ Viewpoint
The rising incidence of kidney cancer, with an estimated 400,000 new cases and approximately 175,000 annual deaths globally, is intensifying the demand for advanced diagnostics. Manufacturers and research institutes are focused on identifying novel biomarkers for improved prognosis and early detection. Concurrently, therapeutic explorations targeting extracellular vesicles (EVs) as drug delivery systems are set to bolster survival outcomes. These technological advancements and increased R&D funding are expected to drive the market's robust growth.
Key Market Drivers
- Increase in Incidence of Kidney Cancer
The growing number of new kidney cancer cases worldwide is a primary growth driver, necessitating early and precise diagnostic procedures. - Surge in Diagnostic Procedures
Enhanced adoption of advanced diagnostic techniques, including biopsy, imaging tests, and blood tests, is improving early detection and treatment efficiency. - Research and Development Initiatives
Increased funding for kidney cancer research is accelerating the development of innovative diagnostic markers and therapeutic solutions. - Rising Geriatric Population
An aging global population, particularly in regions like North America, is propelling demand as older adults are more prone to kidney cancer.
Key Developments & Competitive Landscape
Recent years have witnessed a transformative shift in kidney cancer diagnostics, marked by several key developments that are reshaping the field. One of the most notable advancements is the integration of artificial intelligence and machine learning algorithms into diagnostic protocols, which has markedly improved the speed and accuracy of cancer detection. These technologies analyze complex datasets to uncover subtle indicators of tumor presence, thereby providing clinicians with critical insights that inform treatment decisions.
Additionally, breakthroughs in imaging technology have resulted in the development of novel diagnostic agents capable of precisely targeting renal tumors, reducing the need for invasive procedures such as biopsies. The advent of non-invasive diagnostic tests, including innovative urine-based assays, further underscores the industry's commitment to enhancing patient comfort and diagnostic reliability. These developments, supported by increased research and development investments, are setting a new standard in kidney cancer care and paving the way for more effective and efficient diagnostic approaches.
Innovative Biomarker Discovery
Recent studies have identified higher BIRC5 expression as a reliable indicator for clear cell renal cell carcinoma (ccRCC), promising improved diagnostic accuracy.
Therapeutic Advancements
In July 2022, Bristol-Myers Squibb announced positive results from its Phase III trial combining Opdivo and Yervoy for RCC, underscoring the importance of integrated diagnostic and therapeutic strategies.
Research Funding Boosts
In September 2022, the Department of Defense’s Kidney Cancer Research Program granted US$ 1 Mn to Weill Cornell Medicine to study the role of protein ATF4 in ccRCC.
Key Market Players
Leading companies are actively investing in new product development and innovative diagnostic tools. Notable players include:
- Siemens Healthineers
- Koninklijke Philips N.V.
- FUJIFILM Holdings Corporation
- Grail
- Laboratory Corporation of America Holdings
- Thermo Fisher Scientific
- Myriad Genetics, Inc.
- Canon Medical Systems Corporation
- QIAGEN N.V.
- Illumina, Inc.
- Ambry Genetics
- Invitae Corp.
- Centogene N.V.
Gain an understanding of key findings from our Report in this sample –
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=78590
Market Segmentation
By Product Type:
Platform-based Products, Instrument-based Products, Kits and Reagents, Others (Consumables, etc.)
By Test Type:
Biopsy, Imaging Tests, Blood Tests, Others (Genetic Testing, etc.)
By Cancer Stage:
Stage 1, Stage 2, Stage 3, Stage 4
By Tumor Type:
Renal Cell Carcinoma, Clear Cell Carcinoma, Non-clear Cell Carcinoma
By Technology:
Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Others (Immunohistochemical, etc.)
By End-User:
Hospitals, Cancer Research Centers, Oncology Clinics, Diagnostic Centers, Ambulatory Surgery Centers, Others (Research Institutes, etc.)
By Region:
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Buy this Premium Research Report for a detailed exploration of industry insights -
https://www.transparencymarketresearch.com/checkout.php?rep_id=78590<ype=S
Regional Outlook
The global kidney cancer diagnostics market is characterized by distinct regional trends that reflect variations in healthcare infrastructure, economic conditions, and government priorities. North America continues to lead the market, buoyed by high healthcare expenditure, advanced medical facilities, and a strong emphasis on early cancer detection and research. The region's proactive investment in cutting-edge diagnostic technologies has solidified its position as a global leader. In Europe, the market is similarly robust, supported by the presence of major industry players, supportive regulatory frameworks, and widespread adoption of precision medicine practices.
Meanwhile, the Asia-Pacific region is poised for significant expansion due to rapidly increasing healthcare investments, a growing population, and government initiatives aimed at enhancing cancer research and early detection. Although markets in Latin America and the Middle East & Africa are still emerging, they are gradually showing positive trends as improvements in healthcare access and diagnostic capabilities continue to take hold. Overall, while North America and Europe remain the frontrunners, the global landscape is evolving, with the Asia-Pacific region anticipated to play an increasingly important role in the future of kidney cancer diagnostics.
Leading Region: North America
North America dominated the kidney cancer diagnostics landscape in 2023, propelled by substantial R&D investments and a high prevalence of the disease among the aging population. In the U.S., nearly 79,000 new kidney cancer cases were reported in 2022, while Canada saw approximately 8,000 cases, underscoring the region’s leading market position.
Frequently Asked Questions (FAQs)
How big was the kidney cancer diagnostics market in 2023?
- The market was valued at US$ 3.6 Billion in 2023.
What is the forecasted market value by 2034?
- It is expected to reach US$ 6.9 Billion by the end of 2034.
Which factors are driving market growth?
- Rising incidence of kidney cancer, increased diagnostic procedures, and enhanced R&D initiatives are key drivers.
Which region dominates the market?
- North America continues to lead the kidney cancer diagnostics landscape.
Who are the key players in the market?
- Notable companies include Siemens Healthineers, Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Grail, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, and others.
Explore Latest Research Reports by Transparency Market Research:
The global industry was valued at US$ 4.4 Bn in 2022. It is estimated to grow at a CAGR of 8.0% from 2023 to 2031 and reach US$ 8.8 Bn by the end of 2031.
The industry was valued at US$ 26.9 Bn in 2022. It is estimated to grow at a CAGR of 4.6% from 2023 to 2031 and reach US$ 40.1 Bn by the end of 2031.
Proliferative Diabetic Retinopathy Market -
The industry was valued at US$ 2.5 Bn in 2022. It is estimated to grow at a CAGR of 5.8% from 2023 to 2031 and reach US$ 4.1 Bn by the end of 2031.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Editor Details
-
Company:
- Transparency Market Research
-
Name:
- Rahul Mengane
- Email:
-
Telephone:
- +448455651771
- Website:
Related Links
- Website: Kidney Cancer Diagnostics Market
